Alessandra Recchia

Prof. Alessandra Recchia

University of Modena and Reggio Emilia
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2013 in Blood
Verified
Journal Article
Closed access
PDF file
NCNicoletta Cieri
Nicoletta Cieri
BCBarbara Camisa
Barbara Camisa
FCFabienne Cocchiarella
Fabienne Cocchiarella
MFMattia Forcato
Mattia Forcato
GOGiacomo Oliveira
Giacomo Oliveira
CBChiara Bonini
Chiara Bonini
Long-living memory stem T cells (TSCM) with the ability to self-renew and the plasticity to differentiate into potent effectors could be valuable weapons in adoptive T-cell therapy against cancer. Nonetheless, procedures to specifically target this T-cell population remain elusive. Here, we show that it is possible to differentiate in vitro, expand, and gene modify in clinically compliant conditions CD8+ TSCM lymphocytes starting from naive precursors. Requirements for the generation of this T-cell subset, described as CD62L+CCR7+CD45RA+CD45R0+IL-7Rα+CD95+, are CD3/CD28 engagement and culture with IL-7 and IL-15. Accordingly, TSCM accumulates early after hematopoietic stem cell transplantation. The gene expression signature and functional phenotype define this population as a distinct memory T-lymphocyte subset, intermediate between naive and central memory cells. When transplanted in immunodeficient mice, gene-modified naive-derived TSCM prove superior to other memory lymphocytes for the ability to expand and differentiate into effectors able to mediate a potent xenogeneic GVHD. Furthermore, gene-modified TSCM are the only T-cell subset able to expand and mediate GVHD on serial transplantation, suggesting self-renewal capacity in a clinically relevant setting. These findings provide novel insights into the origin and requirements for TSCM generation and pave the way for their clinical rapid exploitation in adoptive cell therapy.

19 November 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FMFulvio Mavilio
Fulvio Mavilio
GPGraziella Pellegrini
Graziella Pellegrini
SFStefano Ferrari
Stefano Ferrari
FNFrancesca Di Nunzio
Francesca Di Nunzio
EIEnzo Di Iorio
Enzo Di Iorio
MLMichele De Luca
Michele De Luca

26 December 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MHMaarten Holkers
Maarten Holkers
IMIgnazio Maggio
Ignazio Maggio
JLJin Liu
Jin Liu
JJJosephine M. Janssen
Josephine M. Janssen
FMFrancesca Miselli
Francesca Miselli
MGManuel Goncalves
Manuel Goncalves
The array of genome editing strategies based on targeted double-stranded DNA break formation have recently been enriched through the introduction of transcription activator-like type III effector (TALE) nucleases (TALENs). To advance the testing of TALE-based approaches, it will be crucial to deliver these custom-designed proteins not only into transformed cell types but also into more relevant, chromosomally stable, primary cells. Viral vectors are among the most effective gene transfer vehicles. Here, we investigated the capacity of human immunodeficiency virus type 1- and adenovirus-based vectors to package and deliver functional TALEN genes into various human cell types. To this end, we attempted to assemble particles of these two vector classes, each encoding a monomer of a TALEN pair targeted to a bipartite sequence within the AAVS1 ‘safe harbor’ locus. Vector DNA analyses revealed that adenoviral vectors transferred intact TALEN genes, whereas lentiviral vectors failed to do so, as shown by their heterogeneously sized proviruses in target cells. Importantly, adenoviral vector-mediated TALEN gene delivery resulted in site-specific double-stranded DNA break formation at the intended AAVS1 target site at similarly high levels in both transformed and non-transformed cells. In conclusion, we demonstrate that adenoviral, but not lentiviral, vectors constitute a valuable TALEN gene delivery platform.

15 September 2007 in Blood
Verified
Journal Article
Closed access
CCClaudia Cattoglio
Claudia Cattoglio
GFGiulia Facchini
Giulia Facchini
DSDaniela Sartori
Daniela Sartori
AAAntonella Antonelli
Antonella Antonelli
AMAnnarita Miccio
Annarita Miccio
FMFulvio Mavilio
Fulvio Mavilio
Insertional oncogenesis is a possible consequence of the integration of gamma-retroviral (RV) or lentiviral (LV) vectors into the human genome. RV common insertion sites (CISs) have been identified in hematopoietic malignancies and in the nonmalignant progeny of transduced hematopoietic stem/progenitor cells (HSCs), possibly as a consequence of clonal selection in vivo. We have mapped a large number of RV and LV integrations in human CD34+ HSCs, transduced in vitro and analyzed without selection. Recurrent insertion sites (hot spots) account for more than 21% of the RV integration events, while they are significantly less frequent in the case of LV vectors. RV but not LV hot spots are highly enriched in proto-oncogenes, cancer-associated CISs, and growth-controlling genes, indicating that at least part of the biases observed in the HSC progeny in vivo are characteristics of RV integration, already present in nontransplanted cells. Genes involved in hematopoietic and immune system development are targeted at high frequency and enriched in hot spots, suggesting that the CD34+ gene expression program is instrumental in directing RV integration. The lower propensity of LV vectors for integrating in potentially dangerous regions of the human genome may be a factor determining a better safety profile for gene therapy applications.

1 August 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
BCBarbara Cassani
Barbara Cassani
GAGrazia Andolfi
Grazia Andolfi
MMMassimiliano Mirolo
Massimiliano Mirolo
LBLuca Biasco
Luca Biasco
CBClaudio Bordignon
Claudio Bordignon
Gene transfer into HSCs is an effective treatment for SCID, although potentially limited by the risk of insertional mutagenesis. We performed a genome-wide analysis of retroviral vector integrations in genetically corrected HSCs and their multilineage progeny before and up to 47 months after transplantation into 5 patients with adenosine deaminase–deficient SCID. Gene-dense regions, promoters, and transcriptionally active genes were preferred retroviral integrations sites (RISs) both in preinfusion transduced CD34+ cells and in vivo after gene therapy. The occurrence of insertion sites proximal to protooncogenes or genes controlling cell growth and self renewal, including LMO2, was not associated with clonal selection or expansion in vivo. Clonal analysis of long-term repopulating cell progeny in vivo revealed highly polyclonal T cell populations and shared RISs among multiple lineages, demonstrating the engraftment of multipotent HSCs. These data have important implications for the biology of retroviral vectors, the dynamics of genetically modified HSCs, and the safety of gene therapy.

22 November 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RGRichard Gabriel
Richard Gabriel
RERalph Eckenberg
Ralph Eckenberg
APAnna Paruzynski
Anna Paruzynski
CBCynthia C Bartholomae
Cynthia C Bartholomae
ANAli Nowrouzi
Ali Nowrouzi
MSManfred Schmidt
Manfred Schmidt